Organogenesis (NASDAQ:ORGO) Releases Earnings Results, Beats Estimates By $0.11 EPS

Organogenesis (NASDAQ:ORGO) released its quarterly earnings data on Tuesday. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.11, Zacks reports. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The firm had revenue of $115.18 million during the quarter, compared to analyst estimates of $109.59 million. During the same quarter in the prior year, the firm posted $0.02 earnings per share. Organogenesis updated its FY 2024 guidance to EPS.

Organogenesis Trading Down 3.7 %

Shares of Organogenesis stock traded down $0.15 during trading on Friday, hitting $3.86. The stock had a trading volume of 211,683 shares, compared to its average volume of 823,032. The stock has a market cap of $511.76 million, a PE ratio of -63.50 and a beta of 1.60. The firm’s fifty day simple moving average is $2.97 and its 200-day simple moving average is $2.81. Organogenesis has a 12 month low of $2.16 and a 12 month high of $4.70. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.42.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.